Navigation Links
drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007
Date:2/6/2008

in the company's financial reporting. However, adjusted EBITDA should not be considered in isolation, or as a substitute for, or as superior to, net income/loss, cash flows, or other consolidated income/loss or cash flow data prepared in accordance with GAAP, or as a measure of the company's profitability or liquidity. Although adjusted EBITDA is frequently used as a measure of operating performance, it is not necessarily comparable to other similarly titled captions of other companies due to differences in methods of calculation. Net income/loss is the closest financial measure prepared by the company in accordance with GAAP in terms of comparability to adjusted EBITDA. A reconciliation of adjusted EBITDA to net income/loss is included with the financial statements attached to this release.

drugstore.com, inc. also uses non-GAAP measures in which CNS sales are excluded from OTC segment sales data. This non-GAAP measure is provided to enhance the user's overall understanding of the company's financial performance in the OTC segment. Management believes that these reporting metrics provide useful information to the company and to investors by excluding certain items that may not be indicative of the company's core operating results in the OTC segment. By excluding CNS sales from OTC sales data, the company can more effectively assess the buying behavior of, and the company's financial performance with respect to, its own core OTC customers (those customers making nonprescription purchases through Web sites owned by drugstore.com, inc. and its subsidiaries). However, these non-GAAP measures should not be considered in isolation, or as a substitute for, or as superior to, OTC segment sales data prepared in accordance with GAAP, or as a measure of the company's overall performance in the OTC segment. OTC segment sales measures are the closest financial measures prepared by the company in accordance with GAAP in terms of comparability to OTC segment sales measures
'/>"/>

SOURCE drugstore.com, inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. drugstore.com inc. Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007
2. drugstore.com, inc. to Announce Third Quarter 2007 Results During Conference Call on Monday, October 22, 2007 at 5:00 p.m. ET
3. drugstore.com and Revolution Health Group Announce Breakthrough Deal
4. TyraTech Achieves Insecticide Development and Financial Milestones With Partner Arysta LifeScience
5. Joint Commission International Achieves Accreditation from ISQua
6. Cethromycin achieves all endpoints in second pivotal Phase III Trial for treatment for pneumonia
7. Halogen Software Achieves Most Successful Quarter in Company History - Includes Record Year-Over-Year Overall and License Revenue
8. Pharsight Achieves $7.3 Million in Quarterly Revenue
9. ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent
10. LMS integrated obstetrics solution achieves general availability
11. OSF HealthCare Achieves Impressive Tobacco Quit Rates with the Free & Clear(R) Quit For Life(TM) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...ifficult to treat the malignancy, experts explain ...omen who have had their breasts augmented with imp...ast cancer may be treated successfully with a part...apy, according to an Arizona physician and researc...hese augmented women," said Dr. Robert Kuske Jr., ...
(Date:12/1/2008)...next time you visit a dentist,in the mid-Michigan... pressure,in addition to your brushing habits. ,...edical Center/McLaren Health,Care and the Michiga...t,project designed to have dentists and physician...ood pressure in patients. , "Dentists are t...
(Date:12/1/2008)...ire/ -- As part of the Dec. 1 observance of Worl...mes today urged Pennsylvanians to be tested for HI...d ongoing efforts to educate the public about the ...essage is clear: regardless of your personal backg...V is the only sure way to know your status and to ...
(Date:12/1/2008)...ive alternative to conventional angiography for ev...nary artery disease; true even if the patients hav...a study performed at the Thomas Jefferson Universi...ded 31 patients who had one or more calcified coro...ronary CTA. Calcified plaques in the arteries were...
Breaking Medicine News(10 mins):Health News:Radioactive 'Seed' Rx Helps Women With Implants Fight Breast Cancer 2Health News:Radioactive 'Seed' Rx Helps Women With Implants Fight Breast Cancer 3Health News:Dental and Medical Communities Piloting Partnership in Mid-Michigan To Detect and Defeat Disease 2Health News:Dental and Medical Communities Piloting Partnership in Mid-Michigan To Detect and Defeat Disease 3Health News:PA Department of Health Recognizes 20th Anniversary of World AIDS Day; Urges HIV Testing 2
...nglo-American company has been allowed to store wh...ure by the US Food and Drug Administration. White... system that defend the body against both infectio...materials. The company will reportedly take 480-mi...
...nvironmental group Friday welcomed the European Un...ade which causes environmental pollution, and urge...ink and other green groups hailed the EU resolutio...oup had called upon governments across the world t...
...United States and other northern mid- and upper-la...tting global warming than previously thought , acc...f Science. The study, which sheds light on the so-...s that intact tropical forests are removing an une...
...man Jim Carreys lady love Jenny McCarthy has revea...er . The actress insisted that the couple will be ...Beach beach beach beach beach. We like to sit and .... Stare at the ocean and go 'ohhmmm, People quoted...
Other Medicine News:Health News:Northern Forests Less Effective Than Tropical Forests in Reducing Global Warming 2Health News:Northern Forests Less Effective Than Tropical Forests in Reducing Global Warming 3
(Date:11/25/2008)...ov. 25 Poniard,Pharmace...al company focused on,innovative oncology therapi...ategic alternatives for its preclinical research p...s resources on the clinical development of picopla...he initial commercialization of,picoplatin in the...
(Date:11/25/2008)...-FirstCall/ -- CardioVascular,BioTherapeutics, In...t it has,dosed the first patient in North America...l to treat patients with severe coronary heart dis...f CORonary heart Disease) trial will include,four...s in approximately 120,patients with severe coron...
(Date:11/24/2008)...ewswire-FirstCall/ -- Leaders of Schering-Plough C... for investors on the company,s research pipeline,... includes 46 new entities in clinical trials or un...s. , , "Research and development is adding ...inue our transformation," said Fred Hassan, chairm...
(Date:11/24/2008)... Unveils Rich Development Pipeline of Compounds Me...H, N.J., Nov. 24 Scherin... top-line results of a long-term Phase III clinica...M) (asenapine) demonstrating efficacy and safety i...ial, asenapine was statistically significantly mor...
Breaking Medicine Technology:Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 2CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention 2Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention 3Type 1 diabetes triggered by lazy regulatory T cells 3A McGill researchers 1903 1Type 1 diabetes triggered by lazy regulatory T cells 3A McGill researchers 1903 2Prominent Health Care Executive Kevin Kraushaar Joins Triadvocates LLC as Managing Principal of DC Office 9562 1Prominent Health Care Executive Kevin Kraushaar Joins Triadvocates LLC as Managing Principal of DC Office 9562 2Prominent Health Care Executive Kevin Kraushaar Joins Triadvocates LLC as Managing Principal of DC Office 9562 3Virginia Cares Uninsured Program 28VCUP 29 Announces Early Successes in Helping Uninsured Virginians Access Quality Healthcare 9559 1Virginia Cares Uninsured Program 28VCUP 29 Announces Early Successes in Helping Uninsured Virginians Access Quality Healthcare 9559 2Virginia Cares Uninsured Program 28VCUP 29 Announces Early Successes in Helping Uninsured Virginians Access Quality Healthcare 9559 3Health Options Inc s BlueMedicare HMO Earns NCQA Excellent Rating 9556 1Health Options Inc s BlueMedicare HMO Earns NCQA Excellent Rating 9556 2
...l Approach to Address Growing Problem of Antibioti...NCOUVER, British Columbia, March 26, 2007 /PRNewsw...idate IDR-1 is the first,immune system trigger to ...on, according to a paper published in the April 20...ch highlights the work of Inimex and its,co-founde...
...NCETON, N.J., March 25, 2007 /PRNewswire/ -- Once-...dication tolvaptan, a,vasopressin receptor antagon... symptoms of acutely decompensated heart failure (...nal care, without an,adverse effect on their long-...om the short- and long-term analyses of the,intern...
Other Medicine Technology:Inimex Product Candidate is First Immune Defense Regulator to Cure,Infections Without Causing Harmful Inflammation 2Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 2Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 3Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 4Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 5Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 6Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 7
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
Medicine Products: